MedWatch

Novo Nordisk enters collaboration with Heartseed on cell-based treatment

Through the new agreement, Novo Nordisk gets exclusive rights to develop, produce and market Heartseed's HS-001 product for the treatment of cardiovascular diseases all over the world, excluding Japan.

Photo: Stine Tidsvilde

Novo Nordisk and Heartseed have entered an exclusive global partnership and license agreement over the development, production and marketing of Heartseed's HS-001 to treat cardiovascular diseases, Novo Nordisk reports in a press release.

HS-001 is an investigational cell therapy using purified cardiomyocytes derived from induced pluripotent stem cells (iPSC), which is currently under development by Heartseed for the treatment of heart failure.

Read the whole article

Get 14 days free access.
No credit card required.

An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

CHMP recommends nine new drugs, rejects one

Roche and Biogen are among the companies that have received recommendation for approval from the European Medicines Agency's committee (CHMP) at its September meeting. One Pfizer drug was the sole candidate to be rejected.

CEO at WSA: No clarity on EQT exit plans yet

The time horizon for the venture fund EQT's investment in WS Audiology should be ending soon, but according to Group CEO Eric Bernard, there is no clarity on when the potential changes might occur.

Further reading

Related articles

Trial banner

Latest news

See all jobs